Simple Summary Disease progression and prognosis in PMF are usually associated with worsening of anemia, increase of circulating blasts, and, more recently, with the presence, in addition to the “classical” driver mutations, of JAK2, MPL, and CALR genes, as well as of cytogenetic and molecular abnormalities that have been incorporated into new genetically based prognostic scoring systems. We have […]
MPN Clinical Trials 2021 Update
Patients are Asking – MPN Expert Dr. Andrew Kuykendall Episode 2 of 3 Update on MPN Clinical Trials in 2021. The PDUFA date is the end of the review period, where the FDA has to make a decision or respond to a New Drug Application (NDA) or a Biologics License Application (BLA). Ropeginterferon and Pacritinib […]
Financial Patient Assistance Programs for MPNs
by Lou Ann Donovan The World Health Organization (WHO) published a revised document in 2008 listing MPNs as a blood cancer to promote the recognition of the genetic characterization of myeloid malignancies. Now, there are numerous organizations providing financial support and assistance with travel to a cancer center, copay and medication assistance, and many programs […]
Patients are Asking – MPN Expert Dr. Prithviraj Bose
Episode 1 of 3 in Patients are Asking Series What symptoms should I look for to see if I might be progressing from polycythemia vera to myelofibrosis? When would you typically recommend Next Generation Sequencing (NGS) and what are the benefits? Why does bone & joint pain occur and what are some possible solutions? Dr. […]
